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Background: In the 1980s, Streptococcus pneumoniae and Haemophilus
influenzae were identified as the principal causes of severe pneumonia in
children. We investigated the etiology of severe childhood pneumonia in
Kenya after introduction of conjugate vaccines against H. influenzae type b,
in 2001, and S. pneumoniae, in 2011.
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Methods: We conducted a case–control study between August 2011 and
November 2013 among residents of the Kilifi Health and Demographic
Surveillance System 28 days to 59 months of age. Cases were hospitalized
at Kilifi County Hospital with severe or very severe pneumonia according
to the 2005 World Health Organization definition. Controls were randomly
selected from the community and frequency matched to cases on age and
season. We tested nasal and oropharyngeal samples, sputum, pleural fluid,
and blood specimens and used the Pneumonia Etiology Research for Child
Health Integrated Analysis, combining latent class analysis and Bayesian
methods, to attribute etiology.
Results: We enrolled 630 and 863 HIV-uninfected cases and controls,
respectively. Among the cases, 282 (44%) had abnormal chest radiographs
(CXR positive), 33 (5%) died in hospital, and 177 (28%) had diagnoses
other than pneumonia at discharge. Among CXR-positive pneumonia cases,
viruses and bacteria accounted for 77% (95% CrI: 67%–85%) and 16%
(95% CrI: 10%–26%) of pneumonia attribution, respectively. Respiratory
syncytial virus, S. pneumoniae and H. influenza, accounted for 37% (95%
CrI: 31%–44%), 5% (95% CrI: 3%–9%), and 6% (95% CrI: 2%–11%),
respectively.
Conclusions: Respiratory syncytial virus was the main cause of CXR-positive pneumonia. The small contribution of H. influenzae type b and pneumococcus to pneumonia may reflect the impact of vaccine introductions in
this population.
Key Words: Kenya, pneumonia, etiology, childhood, Pneumonia Etiology
Research for Child Health
(Pediatr Infect Dis J 2021;40:S29–S39)

P

neumonia is the leading cause of death in children <5 years
of age in developing countries.1 Streptococcus pneumoniae and
Haemophilus influenzae were the main causes of severe pneumonia
and the principal pathogens against which treatment is targeted in
the Integrated Management of Childhood illness guidelines.2
H. influenzae type b (Hib) vaccine and the 10-valent pneumococcal conjugate vaccine (PCV10) were introduced into the
Kenya National Immunization Program in November 2001 and
January 2011, respectively. In Kilifi, invasive disease caused by
Hib declined by 88% in the 3 years after the vaccine was introduced3 and this was sustained for a further 9 years.4 PCV10 was
introduced in Kilifi with a catch-up campaign for children 12–59
months of age to accelerate herd protection.5 At the end of 2011,
vaccine coverage in children 2–11 months (≥2 doses) and 12–59
months (≥1 dose) was 80% and 66%, respectively.6 By 2016, the
incidence of invasive pneumococcal disease caused by vaccine
serotypes declined by 92% among children <5 years of age6; the
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incidence of radiologically confirmed pneumonia and clinically
defined pneumonia declined by 48% and 27%, respectively.7
Given the success of these vaccines across the world,8–10 the
etiologic profile of childhood pneumonia is expected to change following their introduction. The remaining pathogens are likely to
be more diverse, and current treatment strategies against childhood
pneumonia are likely to be ineffective. We need to direct new drug
and vaccine development against the remaining pathogens.11,12
The Pneumonia Etiology Research for Child Health
(PERCH) study was a 7-country case–control study evaluating the
etiology of pneumonia among hospitalized children in developing
countries.13 In Kilifi, PERCH was nested within the Kilifi Health
and Demographic Surveillance System (KHDSS), which has conducted long-term surveillance of invasive bacterial diseases and
viral respiratory pathogens for 2 decades. Kilifi is typical of much
of rural sub-Saharan Africa, with low HIV prevalence, a mature
Hib vaccine program and a recent PCV program.

STUDY POPULATION AND METHODS
Study Site
KHDSS covers an area of 891 km2 around Kilifi County
Hospital (KCH) located on the Kenya Coast and follows a population of approximately 270,000 for vital events and migration,
through 4 monthly household visits. Hospitalization at KCH,
including electronic clinical and laboratory records, is captured in
the KHDSS database through real-time linkage of each patient to
the KHDSS population register.14
Kilifi County has a predominantly rural population of subsistence farmers, 58% of whom live below the National poverty
line.15 It has 2 rainy seasons: April to July and October to December.16 Malaria transmission peaks during the rainy seasons, but
overall, malaria has been declining over the last 15 years.17 Under
5 and infant mortality ratios in the KHDSS were 34.6 and 23.4 per
1000 live births, respectively, between 2011 and 2013. Pneumonia
and malaria were the principal causes of death among infants and
children 1–4 years of age, respectively, between 2008 and 2011.18
Annual HIV prevalence estimates among women attending antenatal screening at KCH were 2.6%–3.2% between 2011 and 2013.
The prevalence of wasting, underweight and stunting (given as Z
scores of <−2 SD in weight-for-height, weight-for-age and heightfor-age) were 4%, 17% and 39%, respectively, in children <5 years
of age in Kilifi County.19

Selection of Participants
All pediatric admissions to KCH from August 15, 2011, to
November 15, 2013, were screened for eligibility. Clinical officers
assessed most children at the outpatient clinic; very sick children,
or those presenting out of hours, were assessed on the pediatric
wards. Study clinicians examined all admissions and recorded
clinical data directly onto a standardized computer record. Children 28 days to 59 months of age, resident within the KHDSS and
admitted with clinical features of 2005 World Health Organization
(WHO)-defined severe or very severe pneumonia, were eligible to
participate.20,21 Eligibility was assessed in real time by a computer
algorithm applying PERCH inclusion and exclusion criteria (Table,
Supplemental Digital Content 1, http://links.lww.com/INF/D871).
Between December 7, 2012, and February 11, 2013, recruitment was interrupted by a nationwide nurses’ strike which closed
the general pediatric ward. During this time, recruitment was
restricted to very sick children in the High Dependency Unit. The
study was extended by 3 months (August 16 to November 15, 2013)
to compensate for this interruption.
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Controls were selected randomly from the KHDSS population register. Children were eligible if they did not have WHOdefined severe or very severe pneumonia. They were frequency
matched to cases by age and season but with a minimum monthly
recruitment target of 25 controls. We visited a homestead ≥3 times
before concluding that the selected control was unavailable and
choosing a replacement from the random list. For controls, enrolment and sample collection was done at participants’ homes.

Clinical Samples and Laboratory Analyses
At admission, blood samples were collected for culture,
serology, microscopic examination for malaria parasites, and polymerase chain reaction (PCR) to detect S. pneumoniae. Rapid HIV
antibody testing was done as part of routine care. Nasopharyngeal
and oropharyngeal swab (NPOP) samples were collected within 8
hours of admission for PCR testing using a 33-pathogen multiplex
quantitative PCR (FTD Resp-33; Fast-track Diagnostics, Sliema,
Malta) and pneumococcal culture (NP swabs only). Induced sputum (IS) samples, for culture, Mycobacterium tuberculosis (MTB)
and PCR testing, were collected within 24 hours of admission. In
children with suspected MTB, a second IS sample was collected
for additional MTB testing 48 hours after admission or a gastric
aspirate sample where IS was clinically contraindicated. Pleural fluid samples were collected for culture and PCR in children
where a pleural tap was clinically indicated. Lung aspirates were
not obtained. CXRs were obtained from cases at the earliest opportunity after admission and interpreted by a trained reading panel.22
CXRs were classified as abnormal if there was presence of any of
consolidation, pleural effusion or other infiltrate. Abnormal CXRs
are referred to here as CXR positive. All samples collected in cases
were also collected in controls, with the exception of blood for
culture, pleural fluid and IS. Data on antibiotic use were available
from clinical records and serum bioassay results.
Study staff were trained on clinical examination and sample collection using a standardized training curriculum.23 Samples
were processed and analyzed using standardized laboratory methods.24 Data-derived density thresholds were applied to PCR results
for S. pneumoniae, H. influenzae, Pneumocystis jirovecii and cytomegalovirus to optimize sensitivity and specificity.25 –27
At discharge, a nonstudy clinician recorded up to 2 discharge
diagnoses (primary and secondary) into a standardized computer
record, selecting the most appropriate diagnoses from a predefined
list. Cases of pneumonia were classified here as lower respiratory
tract infections (LRTI). Cases of bronchiolitis were classified separately. A senior clinician audited all the discharge diagnoses to
ensure consistency of recordings.

Statistical Analysis and Data Management
Electronic clinical data were exported monthly to a central
coordinating center which undertook data management and statistical analyses for all participating sites.28
The fraction of pneumonia due to each pathogen was estimated using the PERCH Integrated Analysis (PIA) method, which
is described in detail elsewhere.29–31 In brief, the PIA is a Bayesian
nested partially latent class analysis that integrates the results for
each case from blood culture, NP/OP PCR, whole blood PCR for
pneumococcus and IS culture for MTB. The PIA also integrates test
results from controls to account for imperfect test specificity of NP/
OP PCR and whole blood PCR. All analyses were adjusted for age
(<1 versus ≥1 year) to account for differences in pathogen prevalences by this factor. The model assumes that each child’s pneumonia was caused by a single pathogen. The PIA estimated both the
individual- and population-level etiology probability distributions,
each summing to 100% across pathogens where each pathogen
has a probability ranging from 0% to 100%. The population-level
© 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
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etiologic fraction estimate for each pathogen was approximately the
average of the individual case probabilities and was provided with a
95% credible interval (95% CrI), the Bayesian analogue of the confidence interval. The sensitivity priors used in the model are presented in Table, Supplemental Digital Content 11 (http://links.lww.
com/INF/E465). Odds ratios (OR) and 95% confidence intervals
(CI) of pathogens detected on NP/OP PCR in cases compared with
controls were calculated using logistic regression adjusted for age
in months and presence of all other pathogens detected on NP/OP
PCR to account for associations between pathogens. Because the
WHO clinical case definitions have relatively poor specificity for
true lung infection, the primary etiology analysis was restricted to
pneumonia cases with abnormal CXRs. We also restricted to HIVuninfected cases because the etiology of pneumonia is different in
HIV-positive cases.32
A separate integrated etiology model was run with in-hospital
vital status as a covariate, adjusting for the child’s age. This links the
mortality status of the child with the etiology assigned at each iteration of the analysis. To calculate the case fatality ratio (CFR) of respiratory syncytial virus (RSV), the proportion of children who died
among all those assigned to RSV is calculated at each iteration of the
analysis, and those CFRs are averaged across all iterations to obtain
an overall CFR and the distribution of the iteration-specific CFRs is
used to calculate a 95% CrI. This is similarly done for all the remaining (non-RSV) cases at each iteration to obtain a non-RSV CFR.
We described the primary hospital-assigned discharge diagnoses among all admissions (28 days to 59 months of age) and
among PERCH cases and used LRTI recorded in either primary
or secondary discharge diagnoses to estimate specificity of the
PERCH pneumonia case definition.
Descriptive statistical analyses were performed using SAS
9.3 (SAS Institute, Cary, NC), and the integrated etiology analysis
was performed using R Statistical Software 3.3.1 (The R Development Core Team, Vienna, Austria) and Bayesian inference software JAGS 4.2.0 (http://mcmc-jags.sourceforge.net/). The R package used to perform the PERCH Integrated Analysis, named the
Bayesian Analysis Kit for Etiology Research, is publicly available
at https://github.com/zhenkewu/baker.

Ethics
We obtained written informed consent from parents or legal
guardians of all participants. The Kenya Medical Research Institute Ethical review committee and the Oxford University Tropical
Research Ethics Committee approved the study.

RESULTS
Study Participants
Of 7545 children admitted to KCH in the study period, 2202
were KHDSS residents 28 days to 59 months of age; of these, 832
had severe or very severe pneumonia, 784 were eligible for inclusion in PERCH, and 634 were enrolled (Fig. 1). The proportion
who agreed to participate varied by location (72%–100%) and was
lowest among urban dwellers in Kilifi town (Table, Supplemental
Digital Content 2, http://links.lww.com/INF/D872). Among those
who were eligible, those who were enrolled did not differ by age,
sex and pneumonia defining features or in-hospital mortality from
those who were not (Table, Supplemental Digital Content 3, http://
links.lww.com/INF/D873). The incidence of enrolment to PERCH
was higher in locations located closer to KCH (Figure, Supplemental Digital Content 4, http://links.lww.com/INF/D874).
Of 1369 children invited to participate as controls, 889
(65%) were screened and 877 (64%) were eligible, of whom 865
© 2021 The Author(s). Published by Wolters Kluwer Health, Inc. 

PERCH Results, Kenya

(99%) were enrolled (Fig. 1). Controls were well matched to cases
on age and season (Table 1).

Clinical Characteristics
Four (0.6%) cases and 2 (0.2%) controls were HIV positive
and were excluded from further analyses. Clinical characteristics of
HIV-uninfected cases are presented in Table 2. CXRs were obtained
in 96% (602/630); of the 28 cases without a CXR, 5 died before a
CXR was obtained. Eight cases had CXRs obtained >72 hours after
admission and were excluded from analyses restricted or stratified
by CXR findings. Among the 594 remaining cases, 282 (47%) were
CXR positive.

Laboratory Results
Blood was cultured in 629 (99.7%) cases; a pathogen was
isolated in 10 (1.6%) cases overall and in 9 (3.2%) CXR-positive
cases (Table, Supplemental Digital Content 5, http://links.lww.
com/INF/D875). These included 5 S. pneumoniae, 2 H. influenzae
nontype b, and one each of Staphylococcus aureus, Pseudomonas.
aeruginosa (isolated in a child with a normal CXR) and a mixed
infection with Salmonella species and Streptococcus Group A in
1 child. A contaminant was cultured in 51 (8.1%) samples. In all
4 HIV-positive cases, blood cultures were negative. Three pleural
fluid samples were collected: 1 was positive for S. pneumoniae by
culture and PCR; and 2 were positive for S. aureus by culture. Of
the 596 IS specimens, 2 (0.3%) were positive for Mycobacterium
tuberculosis by culture; one of these cases was CXR positive (Table,
Supplemental Digital Content 5, http://links.lww.com/INF/D875).
In the NPOP samples, at least 1 pathogen was detected by
PCR in 99% (588/628) of cases and 98% (813/855) of controls.
The median number of NPOP pathogens detected per case and per
control was 4 (IQR: 3–4) and 3 (IQR: 2–4), respectively (Table,
Supplemental Digital Content 6, http://links.lww.com/INF/D876).
Among 581 cases with available data on time and date of antibiotic administration at admission, NPOP specimens were collected
before antibiotic administration in 355 (58%). There was seasonal
variation in the isolation of RSV, rhinovirus, human metapneumovirus and parainfluenza virus 1–4 (Figure, Supplemental Digital
Content 7, http://links.lww.com/INF/D877). NPOP and whole
blood PCR findings are presented in Table, Supplemental Digital
Content 8, http://links.lww.com/INF/D878.

Etiology Results
In the PIA model, the main causes of CXR-positive pneumonia were viruses (77%; 95% CrI: 67%–85%), with RSV being
the most common (37%; 95% CrI: 31%–44%, Fig. 2A–2D and
Table, Supplemental Digital Content 9, http://links.lww.com/INF/
D879). H. influenzae (6%; 95% CrI: 2%–11%) and S. pneumoniae
(5%; 95% CrI: 3%–9%) were the most common bacterial causes
(Fig. 2A and Table, Supplemental Digital Content 9, http://links.
lww.com/INF/D879). Among those over 1 year of age, rhinovirus was the most common pathogen (29%; 95% CrI: 18%–42%,
Fig. 2B and Table, Supplemental Digital Content 9, http://links.
lww.com/INF/D879). The CFRs for RSV and non-RSV cases were
1.6 (95% CrI: 0–4.4) and 8.1 (95% CrI: 6.4–9.6), respectively.

Discharge Diagnoses
LRTI was a primary discharge diagnosis in 25% of all
admissions and 66% of WHO-defined severe or very severe
PERCH cases (Fig. 3). Among PERCH cases, 28% (177/634) were
not assigned LRTI in either their primary or secondary discharge
diagnosis (Table, Supplemental Digital Content 10, http://links.
lww.com/INF/D880). The percentage without LRTI was higher for
very severe pneumonia (42%, 135/324) than for severe pneumonia
www.pidj.com |
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FIGURE 1. Recruitment flow chart. Left, Case recruitment. Right, Control recruitment.
(14%, 42/310, P < 0.005). Among 284 CXR-positive cases, 42
(15%) did not have a discharge diagnosis of LRTI (Fig. 3 and Table,
Supplemental Digital Content 10, http://links.lww.com/INF/D880),
including 23 (8%) whose CXRs showed consolidation or effusion
according to the radiologic reading standard.33

DISCUSSION
Using an integrated analysis of all available etiology data,
we found that viruses accounted for 77% of the attribution of
CXR-positive pneumonia among HIV-uninfected children with
WHO-defined severe or very severe pneumonia in Kilifi, Kenya.
RSV and rhinovirus were the commonest viral causes accounting
for 37% and 14%, respectively. S. pneumoniae and H. influenzae,
which were the main causes of radiologically confirmed pneumonia
(consolidation with or without pleural effusion) in the prevaccine
era, accounted for only 11% of CXR-positive cases (consolidation,
infiltrates or pleural effusion) in our study.
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In the Kilifi PERCH site, and also in Bangladesh, the proportion of pneumonia attributed to viruses, 77% and 78%, respectively,
was substantially higher than the average across the 7 PERCH sites
(61%).31 We undertook a pilot study for the PERCH methods in
Kilifi among children 1–59 months of age between January and
December 2010.34 In the pilot study, a cause was determined in
only 33% of pneumonia cases: virus-only infections in 25%, bacterial only in 6% and mixed viral-bacterial infections in 1% of cases
in an analysis of blood culture and NP sample results. The pilot
study was typical of previous etiology research in that children
with no positive tests were designated “unknown cause” and in our
study they accounted for 67% of all cases investigated. In the main
study, we assigned each child an equal prior probability of etiology
for each of the 33 pathogens tested by PCR and generated posterior probabilities based on the individual pattern of test results
so that a cause was assigned for every case. This novel approach
provides an indication of viral etiology in a much larger proportion of cases. This, in turn, presents a clinical challenge to identify,
© 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
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TABLE 1. Demographic Characteristics of HIV-Uninfected Cases and Controls
All Cases (N = 630*)

Age
 28 days to 5 m
 6–11 m
 12–23 m
 24–59 m
Sex
 Male
 Female
Season of enrolment
 Rainy (Apr to Jul, Oct to Dec)
 Dry (Jan to Mar, Aug to Sep)
HIV exposure status
 Exposed‡
 Unexposed
Malaria slide
 Negative
 Positive
Mid upper arm circumference§
 
≥11.5 cm
 <11.5 cm
Weight-for-height Z scores
 >−2
 −3 to −2
 <−3
Weight-for-age Z scores
 >−2
 −3 to −2
 <−3
Height-for-age Z scores
 >−2
 −3 to −2
 <−3
PCV10 vaccination status¶
 None
 Fully vaccinated (<1 year)
 Fully vaccinated (≥1 year)
Pentavalent vaccination status║
 None
 Fully vaccinated (<1 year)
 Fully vaccinated (≥1 year)
Serum antibiotic activity
 No
 Yes
Parental report of antibiotic use
 No
 Yes
Prior exposure to antibiotics**
 No
 Yes

CXR Abnormal† (N = 282*)

CXR Normal (N = 284*)

Controls (N = 863*)

n (%)

n (%)

n (%)

n (%)

209 (33)
130 (21)
167 (27)
124 (20)

90 (32)
66 (23)
79 (28)
47 (17)

86 (30)
51 (18)
78 (28)
69 (24)

234 (27)
190 (22)
247 (29)
192 (22)

369 (59)
261 (41)

152 (54)
130 (46)

179 (63)
105 (37)

452 (52)
410 (48)

374 (60)
256 (41)

166 (59)
116 (41)

167 (59)
117 (41)

478 (55)
385 (45)

71 (11)
559 (89)

34 (12)
248 (88)

30 (11)
254 (89)

144 (17)
719 (83)

583 (93)
43 (7)

271 (97)
9 (3)

252 (89)
30 (11)

797 (98)
15 (2)

370 (89)
48 (12)

166 (87)
24 (13)

178 (90)
19 (10)

611 (99)
8 (1)

425 (70)
105 (18)
74 (12)

177 (66)
56 (21)
36 (13)

207 (75)
36 (13)
33 (12)

801 (94)
30 (4)
22 (3)

358 (57)
131 (21)
135 (22)

146 (52)
65 (23)
68 (24)

172 (61)
56 (20)
53 (19)

710 (83)
109 (13)
38 (4)

383 (63)
124 (20)
104 (17)

158 (58)
68 (25)
47 (17)

184 (66)
48 (17)
47 (17)

508 (59)
173 (20)
178 (21)

53 (9)
287 (85)
211 (75)

14 (5)
136 (87)
93 (75)

24 (9)
117 (85)
106 (75)

34 (4)
392 (93)
330 (78)

40 (6)
277 (82)
273 (97)

11 (4)
133 (86)
117 (95)

16 (6)
111 (81)
141 (99)

13 (2)
387 (92)
405 (96)

485 (87)
73 (13)

233 (90)
26 (10)

207 (86)
35 (15)

754 (97)
21 (3)

310 (56)
242 (44)

125 (52)
116 (48)

157 (62)
98 (38)

839 (97)
24 (3)

317 (58)
229 (42)

155 (61)
99 (39)

132 (56)
104 (44)

752 (97)
21 (3)

*Restricted to HIV-uninfected participants.
†CXR abnormal defined as chest radiograph finding: consolidation or any other infiltrate.
‡Maternal report of being HIV positive during pregnancy and ELISA results either missing, negative or positive without confirmatory virology test results.
§Restricted to children ≥6 months of age.
¶For children <1 year of age, defined as ≥1 dose and up-to-date for age at enrollment, doses received, and Kenya EPI schedule (allowing 4-week window each for dose). For children ≥1 year of age, defined as 2 doses if given ≥8 weeks apart and child was >1 year of age at first dose; 1 dose if age at any dose or age at introduction was >2 years.
║For children <1 year of age, defined as ≥1 dose and up-to-date for age at enrollment, doses received, and Kenya EPI schedule (allowing 4-week window each for dose). For children ≥1 year of age, defined as 3 doses.
**Defined as serum bioassay positive (cases and controls), antibiotics administered at the referral facility, or antibiotic administration before whole blood specimen collection at
the study facility (cases only); restricted to children with blood specimen collected.

at presentation, the minority of children with a bacterial cause in
order to target antibiotic treatment appropriately.
Compared with the pilot study, the main study also illustrates a
significant change in the blood culture test results; the yield of pneumococci from blood cultures fell from 4% in the pilot study to 0.8%
in the main study. Although blood culture is an insensitive method to
define etiology, the reduction in test positivity is consistent with the
declining incidence of S. pneumoniae disease following pneumococcal
© 2021 The Author(s). Published by Wolters Kluwer Health, Inc. 

vaccine introduction.6,7 PCV10 was introduced in January 2011, immediately after the pilot study terminated, with a catch-up campaign that
reached two-thirds of all children <5 years of age in Kilifi County by
March 20117; the PERCH study began in August 2011. Interrupted time
series analyses, centered on PCV10 introduction, estimated that the incidence of admission with WHO-defined severe or very severe pneumonia and radiologically confirmed pneumonia declined by 27% and 48%,
respectively.7 Of note, the radiologic definition in this impact study was
www.pidj.com |
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TABLE 2. Clinical Characteristics of HIV-Uninfected Cases

Age
 28 days to 5 months
 6–11 months
 12–23 months
 24–59 months
Female
Very severe pneumonia
Case fatality
 Died in hospital
 Died within 30 days of discharge
Chest radiograph findings†
 Taken within 72 h
  
Consolidation
  Other infiltrate only
  
Normal
  
Uninterpretable
 Not taken
  
Child died
  
Other reasons
Clinical characteristics
 Lower chest wall indrawing
 Hypoxemia‡
 Oxygen use at admission
 Tachypnoea
 Tachycardia
 Central cyanosis
 Convulsions
 Lethargy
 Unable to feed
 Vomiting
 Crackles
 Audible wheeze
 Wheeze on auscultation
 Grunting
 Nasal flaring
 Temp >38°C
 Leukocytosis
 CRP ≥ 40 mg/dL
Hemoglobin
 
≤7.5 g/dL
 >7.5 g/dL
Malaria slide positive
HIV exposure status
 Exposed
 Unexposed
 Unknown
MUAC < 11.5 cm║
Weight-for-height Z scores
 >−2
 −3 to ≤−2
 <−3
Weight–for-age Z scores
 >−2
 −3 to ≤−2
 <−3
Height-for-age Z scores
 >−2
 −3 to ≤−2
 <−3
Duration of illness**
 0–2 days
 3–5 days
 >5 days
Duration of hospitalization
 0–2 days
 3–5 days
 >5 days
Antibiotic use
 Prior exposure to antibiotics††
 Parental report of antibiotic use before hospitalization

All Cases
(N = 630)

CXR
Abnormal*
(N = 282)

CXR
consolidation
(N = 119)

n (%)

n (%)

n (%)

209 (33)
130 (21)
167 (27)
124 (20)
261 (41)
323 (51)

90 (32)
66 (23)
79 (28)
47 (17)
130 (46)
114 (40)

49 (41)
20 (17)
26 (22)
14 (12)
58 (49)
55 (46)

33 (5)
6 (1)

17 (6)
1 (0.4)

594 (94)
119 (19)
163 (26)
284 (45)
28 (4)
28 (4)
5 (0.8)
23 (4)

CXR Other
CXR
Severe Very Severe Died in
Infiltrate
Normal
Cases
Cases
Hospital
Only (N = 163) (N = 284) (N = 307) (N = 323)
(N = 33)
n (%)

n (%)

n (%)

n (%)

n (%)

41 (25)
46 (28)
53 (33)
23 (14)
72 (44)
59 (36)

86 (30)
51 (18)
78 (28)
69 (24)
105 (37)
173 (61)

114 (37)
73 (24)
68 (22)
52 (17)
126 (41)
0 (0)

95 (29)
57 (18)
99 (31)
72 (22)
135 (42)
323 (100)

15 (46)
5 (15)
9 (27)
4 (12)
20 (61)
22 (67)

12 (10)
1 (0.8)

5 (3)
0 (0)

9 (3)
3 (1)

11 (4)
3 (1)

22 (7)
3 (1)

33 (100)
0 (0)

282 (100)
119 (42)
163 (58)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)

119 (100)
119 (100)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)

163 (100)
0 (0)
163 (100)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)

284 (100) 291 (95)
0 (0)
64 (21)
0 (0)
104 (34)
284 (100) 111 (36)
0 (0)
12 (4)
0 (0)
10 (3)
0 (0)
1 (0.3)
0 (0)
9 (3)

303 (94)
55 (17)
59 (18)
173 (54)
16 (5)
18 (6)
4 (1)
14 (4)

28 (85)
12 (36)
5 (15)
9 (27)
2 (6)
5 (15)
5 (15)
0 (0)

492 (78)
185 (29)
132 (21)
439 (70)
349 (55)
5 (0.8)
89 (14)
144 (23)
78 (12)
67 (11)
247 (39)
29 (5)
83 (13)
40 (6)
317 (50)
267 (42)
282 (45)
154 (24)

259 (92)
106 (38)
75 (27)
224 (79)
166 (59)
1 (0.4)
16 (6)
55 (20)
36 (13)
14 (5)
134 (48)
13 (5)
41 (15)
23 (8)
166 (59)
128 (45)
145 (51)
78 (28)

110 (92)
57 (48)
42 (35)
99 (83)
77 (65)
0 (0)
4 (3)
27 (23)
22 (19)
6 (5)
60 (50)
4 (3)
15 (13)
11 (9)
76 (64)
59 (50)
64 (54)
46 (39)

149 (91)
49 (30)
33 (20)
125 (77)
89 (55)
1 (0.6)
12 (7)
28 (17)
14 (9)
8 (5)
74 (45)
9 (6)
26 (16)
12 (7)
90 (55)
69 (42)
81 (50)
32 (20)

186 (65)
52 (18)
36 (13)
174 (61)
145 (51)
3 (1)
61 (22)
72 (25)
28 (10)
44 (16)
87 (31)
15 (5)
39 (14)
12 (4)
119 (42)
114 (40)
112 (39)
66 (23)

307 (100)
75 (24)
44 (14)
231 (75)
165 (54)
0 (0)
1§ (0.3)
0 (0)
0 (0)
0 (0)
124 (40)
19 (6)
49 (16)
12 (4)
162 (53)
130 (42)
139 (45)
71 (23)

186 (57)
109 (34)
88 (27)
208 (64)
184 (57)
5 (2)
88 (27)
144 (45)
67 (21)
67 (21)
123 (38)
10 (3)
34 (11)
28 (9)
155 (48)
143 (44)
143 (44)
83 (26)

28 (85)
18 (55)
14 (42)
25 (76)
18 (55)
3 (9)
5 (15)
13 (39)
3 (9)
3 (9)
12 (36)
1 (3)
4 (12)
4 (12)
20 (61)
11 (33)
11 (33)
10 (30)

83 (13)
536 (85)
43 (7)

47 (17)
231 (82)
9 (3)

21 (18)
98 (83)
3 (3)

26 (16)
133 (82)
6 (4)

30 (11)
248 (88)
30 (11)

38 (12)
264 (86)
6 (2)

45 (14)
272 (84)
37 (12)

6 (18)
27 (82)
1 (3)

4 (0.6)
559 (89)
67 (11)
48 (12)

1 (0.4)
248 (88)
33 (12)
24 (13)

0 (0)
101 (85)
18 (15)
8 (11)

1 (0.6)
147 (90)
15 (9)
16 (13)

3 (1)
254 (89)
27 (10)
19 (10)

0 (0)
273 (89)
34 (11)
21 (11)

4 (1)
286 (89)
33 (10)
27 (12)

2 (6)
23 (70)
8 (24)
6 (33)

425 (70)
105 (18)
74 (12)

177 (66)
56 (21)
36 (13)

70 (61)
28 (25)
16 (14)

107 (69)
28 (18)
20 (13)

207 (75)
36 (13)
33 (12)

213 (72)
48 (16)
33 (11)

212 (68)
57 (18)
41 (13)

15 (52)
7 (24)
7 (24)

358 (57)
131 (21)
135 (22)

146 (52)
65 (23)
68 (24)

54 (45)
27 (23)
38 (32)

92 (58)
38 (24)
30 (19)

172 (61)
56 (20)
53 (19)

178 (59)
63 (21)
62 (20)

180 (56)
68 (21)
73 (23)

7 (22)
8 (25)
17 (53)

383 (63)
124 (20)
104 (17)

158 (58)
68 (25)
47 (17)

61 (53)
30 (26)
25 (22)

97 (62)
38 (24)
22 (14)

184 (66)
48 (17)
47 (17)

185 (63)
64 (22)
47 (16)

198 (63)
60 (19)
57 (18)

9 (29)
8 (26)
14 (45)

241 (38)
268 (43)
121 (19)

99 (35)
130 (46)
53 (19)

35 (29)
56 (47)
28 (24)

64 (39)
74 (45)
25 (15)

118 (42)
111 (39)
55 (19)

114 (37)
134 (44)
59 (19)

127 (39)
134 (42)
62 (19)

7 (21)
11 (33)
15 (46)

196 (31)
303 (48)
131 (21)

68 (24)
138 (49)
76 (27)

23 (19)
53 (45)
43 (36)

45 (28)
85 (52)
33 (20)

106 (37)
141 (50)
37 (13)

93 (30)
151 (49)
63 (21)

103 (32)
152 (47)
68 (21)

15 (45)
8 (24)
10 (30)

229 (42)
242 (44)

99 (39)
116 (48)

42 (39)
52 (50)

57 (39)
64 (47)

104 (44)
98 (38)

111 (41)
117 (44)

118 (43)
125 (44)

7 (27)
10 (34)

*CXR abnormal defined as consolidation and/or other infiltrate.
†Eight cases had a CXR obtained more than 3 days after enrollment and their CXR findings were not used in analyses. Other reasons no CXR available included child discharged or absconded
before CXR (N = 9), operator error (N = 1), transferred to another facility (N = 1) and other reasons (N = 12).
‡Hypoxemia defined as oxygen saturation <92% or on supplemental oxygen if a room air oxygen saturation reading was not available (N = 53).
§Single brief convulsion without other very severe case-defining signs.
¶Elevated white blood cells defined as >15 × 109 cells/L for children 1–11 months and >13 × 109 cells/L for children 12–59 months.
║Restricted to children ≥6 months of age.
**Duration of illness defined as maximum days of reported symptoms for any of the following: cough, wheeze, fever or difficulty breathing.
††Defined as serum bioassay positive (cases and controls), antibiotics administered at the referral facility, or antibiotic administration before whole blood specimen collection at the study
facility (cases only); restricted to children with blood specimen collected.
CRP indicates C-reactive protein; MUAC, mid upper arm circumference.
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FIGURE 2. Top 10 causes of radiologically
confirmed pneumonia in HIV-uninfected cases,
stratified by age, severity and CXR findings.
Radiologically confirmed pneumonia defined
by the presence of any of consolidation, pleural
effusion or other infiltrate on chest radiograph.
Description of symbols: Line represents the
95% credible interval. The size of the symbol
is scaled based on the ratio of the estimated
etiologic fraction to its standard error. Of 2
identical etiologic fraction estimates, the estimate
associated with a larger symbol is more informed
by the data than the priors. Panel C Stratified by
WHO 2005 pneumonia case classification: severe
pneumonia, cough or difficulty in breathing
and lower chest wall indrawing without any
danger sign; and very severe pneumonia,
cough or difficulty in breathing and any danger
sign. Flu indicates influenza virus A, B and C;
H. inf, Haemophilus influenzae; HMPV, human
metapneumovirus A/B; Mtb, Mycobacterium
tuberculosis; NoS, not otherwise specified (ie,
pathogens not tested for); P. jirov, P. jirovecii;
Para, parainfluenza virus types 1, 2, 3 and 4; PV/
EV, parechovirus/enterovirus; Rhino, Human
rhinovirus; S. pneu, Streptococcus pneumoniae.

continued
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restricted to consolidation and/or effusion,7,35 whereas
the definition used in PERCH also included abnormal
infiltrates. However, given these substantial changes in
pneumonia incidence attributable to a single pathogen
vaccine, it is not surprising that the contribution of bacteremic pneumococcal pneumonia appears considerably
reduced in PERCH compared with the pilot study.
RSV was the commonest viral cause of pneumonia cases in Kilifi and in all of the other PERCH
sites. Previous studies in Kilifi identified an association between RSV infection in the nasopharynx and
admission with pneumonia34,36; the prevalence of
nasopharyngeal infection was 12%–27% among hospitalized pneumonia cases, 16% among outpatient
controls with upper respiratory tract infections and
2% among healthy controls.16,34,36 RSV infections are
associated with low (2.4%) mortality at KCH.16 In the
PERCH study in Kilifi, the CFRs (estimated using
the integrated analysis) for RSV and for all other
pneumonias were 1.6% (95% CrI: 0–4.4) and 8.1%
(95% CrI: 6.4–9.6), respectively. Although 37%
of pneumonia was attributed to RSV, the low CFR
estimate suggests that RSV is responsible for only a
small fraction of pneumonia deaths in Kilifi.
Rhinovirus was a common infection at all
sites with a prevalence of 17%–36% in cases and
14%–26% in controls. However, it was significantly
associated with case status in only 2 countries; Kenya
(OR 2.4, 95% CI 1.6, 3.7) and Bangladesh (OR 2.5,
95% CI 1.7, 3.7). The prevalence of rhinovirus varies
across time and place, as does the evidence implying
a causal role. In the Kilifi pilot study, for example,
the prevalence of rhinovirus in NP specimens was
23% and 22% in hospitalized cases of WHO-defined
pneumonia and outpatient controls without pneumonia, respectively (OR 1.0, 95% CI 0.7, 1.3).34 In the
South Africa site of the PERCH study, the prevalence
of rhinovirus in cases and controls was 19% and 22%,
respectively (OR = 1.0, 95% CI: 0.5–1.9). However,
in a separate study in South Africa at the same time,
rhinovirus was found in 40% of children <5 years of
age admitted with severe acute respiratory illness and
33% of outpatient controls without respiratory symptoms (aRR = 1.8, 95% CI: 1.4–2.3).37 It is not yet clear
whether rhinovirus is a direct lung pathogen or acts
synergistically to precipitate pneumonia caused by
other pathogens or is falsely implicated by confounding. For example, children from crowded households
are more likely than those from uncrowded households to be exposed to infections of the upper and of
the lower respiratory tract, generating an association
between crowding and pneumonia and an independent association between crowding and pathogens in
the upper respiratory tract.
The WHO clinical definitions of pneumonia
were designed to favor sensitivity over specificity in
order to make life-saving antibiotics widely accessible. In the primary PERCH analysis, we increased
our specificity by analyzing only cases with abnormal CXRs. In Kilifi, we also explored the specificity of these case definitions through an analysis of
the discharge diagnoses among different sub-groups

© 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
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FIGURE 3. Primary discharge diagnoses for children 28 days to 59 months of age admitted at the study hospital during
the PERCH study. WHO Pneumonia classification (2005): severe pneumonia, cough or difficulty in breathing and lower
chest wall indrawing without any danger sign; and very severe pneumonia, cough or difficulty in breathing and any danger
sign. Abnormal chest radiograph: presence of any of consolidation, pleural effusion or other infiltrate on chest radiograph.
Discharge diagnoses (primary and secondary) are recorded in a standard computer form at discharge by nonstudy clinicians
during discharge. The most appropriate diagnoses are selected from a predefined list based on the diagnosis recorded
during the course of the admission. At the study hospital bronchiolitis is differentiated at discharge diagnosis as part of a
longitudinal surveillance program in Kilifi for RSV. In PERCH, children with wheeze/bronchiolitis were excluded from the
study only if their case-defining symptoms (usually lower chest wall indrawing) resolved after bronchodilator treatment.
of PERCH patients (Table, Supplemental Digital Content 10,
http://links.lww.com/INF/D880). These discharge diagnoses were
not part of the PERCH protocol and no attempt was made to standardize interpretations or validate the results. Clinicians identified
non-LRTI conditions in the discharge diagnosis in over a quarter
of all PERCH cases, rising to 42% among very severe pneumonia
cases. Common primary discharge diagnoses for these patients
were malaria (7%), gastroenteritis (5%), malnutrition (4%), febrile
convulsions (3%) and upper respiratory tract infection (2%) illustrating the considerable overlap in clinical presentations between
common pediatric conditions and the limitations of a case definition focused on admission features alone. The clinicians also did
not mention LRTI in the discharge diagnosis of 42 PERCH cases
later classified as having abnormal CXRs by the reading panel,
19 of these had infiltrates only (Table, Supplemental Digital Content 10, http://links.lww.com/INF/D880). Some of the diagnoses
given, including paraffin poisoning (n = 3) and bronchiolitis (n =
4), are compatible with CXR abnormalities. Some children with
predisposition to recurrent pneumonia due to chronic conditions
(eg, congenital heart disease, malnutrition, sickle cell disease)
may have had CXR changes from previous pneumonia episodes.38
The attending pediatrician may have interpreted the radiographs as
negative for pneumonia. Alternatively, the diagnoses selected may
have simply “trumped” pneumonia in a system that only allows
© 2021 The Author(s). Published by Wolters Kluwer Health, Inc. 

the clinician to specify 2 conditions: combinations of malnutrition,
malaria, anemia, febrile convulsions, pulmonary TB, immunosuppression, sepsis, sickle cell disease or meningitis account for 15
of these cases. While the WHO clinical case definitions are essential in case management, they do not always capture the dominant
pathology or illness in a sick child.
Two limitations of this study are noteworthy. The first is
its focus on hospitalized cases.39 Studies from Kilifi have already
documented poor access to care: for example, approximately
40% of very severe pneumonia cases occurring in KHDSS do
not seek care at the study hospital40 and 64% of all childhood
deaths occur outside the hospital.18 The etiology of pneumonia
among cases that do not seek care may differ markedly from
the patterns documented here. Second, available pneumonia
etiology evidence and analytic methods may underestimate the
role of bacteria in pneumonia etiology. Much of the pathologic
evidence for etiology in pneumonia studies comes from nasopharynx,34,41–43 which is frequently colonized by organisms in
the absence of pneumonia. In Kilifi, we have little evidence
from the anatomic site of pathology as we cultured only 3 pleural fluid aspirates and no lung aspirates. Blood cultures were
performed in most children and the PIA model does adjust for
sensitivity and the impact of antibiotics, which were measured
www.pidj.com |
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using a bioassay of serum.29 However, the biologic detection of
antibiotic exposure is insensitive to antibiotics administered ≥8
hours previously because of their short serum half-life. Parental reports of antibiotic administration were much higher than
antibiotics detected in the serum (Table 1), but parental report is
also not a reliable measure.
The PERCH study integrated results from multiple sample
sites from both cases and controls using partial latent class analysis and a Bayesian analytical approach to provide an estimate of
pneumonia etiology in children in Kilifi. Based on these analyses,
77% of the etiology of pneumonia was attributable to viruses, particularly RSV and rhinovirus. This emphasizes the need to advance
vaccines against RSV in children and to understand the pathogenesis of pneumonia involving viral infections. It also significantly
reduces the likelihood that antibiotics will alter the course of
pneumonia illness in a hospitalized child and sets out a significant
challenge to identify the minority of hospitalized cases who do
require antibiotics. The prevalence of bacteremic pneumococcal
pneumonia has declined between the pilot study in 2010 and the
main PERCH study in 2011 to 2013 and this can probably best be
explained by the significant impact of PCV10 on the incidence of
pneumococcal pneumonia.
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